Zusammenfassung
Hintergrund: Pleuraergüsse und Aszites sind unabhängig von der Grunderkrankung mit quälenden Symptomen wie Dyspnoe, Ileus, Erbrechen, Übelkeit und Schmerzen und bei maligner Ursache mit einer limitierten Prognose von wenigen Monaten verbunden. Bei Versagen medikamentöser Therapien kommen chirurgische und experimentelle palliative Therapien zur Anwendung. Methoden: Diese Übersichtsarbeit beinhaltet einen systematischen Review der chirurgischen, experimentellen und palliativen Therapieoptionen. Ergebnisse: Bei malignem Pleuraerguss steht neben der Thorakozentese die permanente transkutane Dränage, der thorakoperitoneale Shunt sowie die Pleurodese über Dränagen oder über eine Thorakoskopie zur Verfügung, die in Abhängigkeit von der Expansionsfähigkeit der Lunge zur Anwendung kommen. Bei chronischen Aszites und Leberzirrhose ist die Anlage eines TIPS das optimale Verfahren. Ansonsten können bei Aszites neben der symptomatischen Parazentese peritoneovenöse Shuntsysteme chirurgisch angelegt werden, die mit hohen Komplikations- und Verschlussraten verbunden sind. Bei malignem Pleuraerguss und Aszites stellt die totale Zytoreduktion und hypertherme Chemoperfusion einen aggressiven chirurgischen Therapieansatz dar, der wenigen geeigneten Patienten vorbehalten bleibt. Bei malignem Aszites stellt die i. p.-Immuntherapie mit Catumaxomab eine neuartige und hoch effektive Option dar, die peritoneale Tumorzellen gezielt zerstören und damit malignen Aszites kontrollieren kann. Schlussfolgerung: Der Behandlung von Pleuraergüssen und Aszites stehen unterschiedliche Optionen zur Verfügung. Eine differenzierte Indikationsstellung und Therapie sind notwendig, um die Lebensqualität und die Prognose zu verbessern.
Abstract
Background: Pleural effusions and ascites are associated with distressing symptoms like dyspnoea, intestinal obstruction, vomiting, nausea and pain. In patients with underlying malignancy, the prognosis is limited to few months. After unsuccessful medical treatment, surgical and experimental palliative treatment is indicated. Methods: This review includes a systematic analysis of surgical, experimental and palliative options. Results: In patients with pleural effusions, thoracocentesis, permanent percutaneous drainage, thoracoperitoneal shunts as well as pleurodesis by tubes or thoracoscopy are available, which will be used depending on the re-expansion of the lung. In patients with ascites, paracentesis is able to control acute symptoms. For long-lasting treatment, portosystemic shunts (TIPS) are favourable for patients with liver cirrhosis. Peritoneovenous shunts can be implanted by laparotomy, but are correlated with high rates of complications and occlusions. In patients with malignancy, pleural effusions and ascites may also be controlled by complete cytoreductive surgery and hyperthermic chemoperfusion. This aggressive surgical concept is limited to single carefully selected patients. In malignant ascites, intraperitoneal immunotherapy by catumaxomab is a novel and highly effective option, which controls ascites by targeted destruction of peritoneal cancer cells. Conclusion: Various options for treatment of pleural effusions and ascites are available. Carful evaluation of the individual patient is necessary to improve quality of life and survival.
Schlüsselwörter
Pleuraerguss - Aszites - Leberzirrhose - Peritonealkarzinose - Pleurodese - Catumaxomab
Key words
pleural effusions - ascites - liver cirrhosis - peritoneal carcinomatosis - pleurodesis - catumaxomab
Literatur
1
Fiocco M, Krasna M J.
The management of malignant pleural and pericardial effusions.
Hematol Oncol Clin North Am.
1997;
11
253-265
2
Sahn S A.
State of the art. The pleura.
Am Rev Respir Dis.
1988;
138
184-234
3
Martinez-Moragon E, Aparicio J, Sanchis J et al.
Malignant pleural effusion: prognostic factors for survival and response to chemical pleurodesis in a series of 120 cases.
Respiration.
1998;
65
108-113
4
Awasthi A, Gupta N, Srinivasan R et al.
Cytopathological spectrum of unusual malignant pleural effusions at a tertiary care centre in north India.
Cytopathology.
2007;
18
28-32
5
Hausheer F H, Yarbro J W.
Diagnosis and treatment of malignant pleural effusion.
Cancer Metastasis Rev.
1987;
6
23-40
6
Boutin C, Astoul P, Seitz B.
The role of thoracoscopy in the evaluation and management of pleural effusions.
Lung.
1990;
168 Suppl
1113-1121
7
Ismail-Khan R, Robinson L A, Williams Jr C C et al.
Malignant pleural mesothelioma: a comprehensive review.
Cancer Control.
2006;
13
255-263
8
Heffner J E, Nietert P J, Barbieri C.
Pleural fluid pH as a predictor of survival for patients with malignant pleural effusions.
Chest.
2000;
117
79-86
9
Irani D R, Underwood R D, Johnson E H et al.
Malignant pleural effusions. A clinical cytopathologic study.
Arch Intern Med.
1987;
147
1133-1136
10
Heffner J E.
Diagnosis and management of malignant pleural effusions.
Respirology.
2008;
13
5-20
11
Chung C L, Chen Y C, Chang S C.
Effect of repeated thoracenteses on fluid characteristics, cytokines, and fibrinolytic activity in malignant pleural effusion.
Chest.
2003;
123
1188-1195
12
Sahn S A.
Management of malignant pleural effusions.
Monaldi Arch Chest Dis.
2001;
56
394-399
13
Feller-Kopman D, Walkey A, Berkowitz D et al.
The relationship of pleural pressure to symptom development during therapeutic thoracentesis.
Chest.
2006;
129
1556-1560
14
Antunes G, Neville E, Duffy J et al.
BTS guidelines for the management of malignant pleural effusions.
Thorax.
2003;
58 Suppl 2
29-38
15
Groth G, Gatzemeier U, Haussingen K et al.
Intrapleural palliative treatment of malignant pleural effusions with mitoxantrone versus placebo (pleural tube alone).
Ann Oncol.
1991;
2
213-215
16
Ohm C, Park D, Vogen M et al.
Use of an indwelling pleural catheter compared with thorascopic talc pleurodesis in the management of malignant pleural effusions.
Am Surg.
2003;
69
198-202
discussion 202
17
Musani A I.
Treatment options for malignant pleural effusion.
Curr Opin Pulm Med.
2009;
15
380-387
18
Tremblay A, Michaud G.
Single-center experience with 250 tunnelled pleural catheter insertions for malignant pleural effusion.
Chest.
2006;
129
362-368
19
Wachsman A M, Hoffer E K, Forauer A R et al.
Tension pneumothorax after placement of a tunneled pleural drainage catheter in a patient with recurrent malignant pleural effusions.
Cardiovasc Intervent Radiol.
2007;
30
531-533
20
Putnam Jr J B, Light R W, Rodriguez R M et al.
A randomized comparison of indwelling pleural catheter and doxycycline pleurodesis in the management of malignant pleural effusions.
Cancer.
1999;
86
1992-1999
21
Chen Y M, Shih J F, Yang K Y et al.
Usefulness of pig-tail catheter for palliative drainage of malignant pleural effusions in cancer patients.
Support Care Cancer.
2000;
8
423-426
22
Pollak J S, Burdge C M, Rosenblatt M et al.
Treatment of malignant pleural effusions with tunneled long-term drainage catheters.
J Vasc Interv Radiol.
2001;
12
201-208
23
Robinson R D, Fullerton D A, Albert J D et al.
Use of pleural Tenckhoff catheter to palliate malignant pleural effusion.
Ann Thorac Surg.
1994;
57
286-288
24
Little A G, Kadowaki M H, Ferguson M K et al.
Pleuro-peritoneal shunting. Alternative therapy for pleural effusions.
Ann Surg.
1988;
208
443-450
25
Genc O, Petrou M, Ladas G et al.
The long-term morbidity of pleuroperitoneal shunts in the management of recurrent malignant effusions.
Eur J Cardiothorac Surg.
2000;
18
143-146
26
Tzeng E, Ferguson M K.
Predicting failure following shunting of pleural effusions.
Chest.
1990;
98
890-893
27
Clementsen P, Evald T, Grode G et al.
Treatment of malignant pleural effusion: pleurodesis using a small percutaneous catheter. A prospective randomized study.
Respir Med.
1998;
92
593-596
28
Parulekar W, Di Primio G, Matzinger F et al.
Use of small-bore vs large-bore chest tubes for treatment of malignant pleural effusions.
Chest.
2001;
120
19-25
29
Sahin U, Unlu M, Akkaya A et al.
The value of small-bore catheter thoracostomy in the treatment of malignant pleural effusions.
Respiration.
2001;
68
501-505
30
Marom E M, Erasmus J J, Herndon 2nd J E et al.
Usefulness of imaging-guided catheter drainage and talc sclerotherapy in patients with metastatic gynecologic malignancies and symptomatic pleural effusions.
AJR Am J Roentgenol.
2002;
179
105-108
31
Ukale V, Bone D, Hillerdal G et al.
The impact of pleurodesis in malignant effusion on respiratory function.
Respir Med.
1999;
93
898-902
32
Hoksch B, Seidel N, Beshay M et al.
[The thoracoscopic talc pleurodesis with intraoperative pleural biopsy – a retrospective analysis in patients with malignant pleural effusion].
Zentralbl Chir.
2010;
135
54-58
33 Shaw P, Agarwal R. Pleurodesis for malignant pleural effusions. Cochrane Database Syst Rev 2004:CD002916
34
Brant A, Eaton T.
Serious complications with talc slurry pleurodesis.
Respirology.
2001;
6
181-185
35
Gushchin V, Demmy T L, Kane 3rd J M.
Surgical management of metastatic peritoneal or pleural disease.
Semin Oncol.
2007;
34
215-225
36
Ludwig C, Stoelben E.
[Surgical therapy for malignant pleural effusions].
Zentralbl Chir.
2008;
133
218-221
37
Arapis K, Caliandro R, Stern J B et al.
Thoracoscopic palliative treatment of malignant pleural effusions: results in 273 patients.
Surg Endosc.
2006;
20
919-923
38
Runyon B A.
Management of adult patients with ascites due to cirrhosis: an update.
Hepatology.
2009;
49
2087-2107
39
Gines P, Cardenas A, Arroyo V et al.
Management of cirrhosis and ascites.
N Engl J Med.
2004;
350
1646-1654
40
Gines P, Quintero E, Arroyo V et al.
Compensated cirrhosis: natural history and prognostic factors.
Hepatology.
1987;
7
122-128
41
Planas R, Montoliu S, Balleste B et al.
Natural history of patients hospitalized for management of cirrhotic ascites.
Clin Gastroenterol Hepatol.
2006;
4
1385-1394
42
Parsons S L, Watson S A, Steele R J.
Malignant ascites.
Br J Surg.
1996;
83
6-14
43
Runyon B A.
Management of adult patients with ascites due to cirrhosis.
Hepatology.
2004;
39
841-856
44
Haynes G R, Navickis R J, Wilkes M M.
Albumin administration – what is the evidence of clinical benefit? A systematic review of randomized controlled trials.
Eur J Anaesthesiol.
2003;
20
771-793
45
Rossle M, Ochs A, Gulberg V et al.
A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites.
N Engl J Med.
2000;
342
1701-1707
46
Albillos A, Banares R, Gonzalez M et al.
A meta-analysis of transjugular intrahepatic portosystemic shunt versus paracentesis for refractory ascites.
J Hepatol.
2005;
43
990-996
47
Sanyal A J, Genning C, Reddy K R et al.
The North American Study for the Treatment of Refractory Ascites.
Gastroenterology.
2003;
124
634-641
48
Salerno F, Camma C, Enea M et al.
Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data.
Gastroenterology.
2007;
133
825-834
49
Bureau C, Garcia-Pagan J C, Otal P et al.
Improved clinical outcome using polytetrafluoroethylene-coated stents for TIPS: results of a randomized study.
Gastroenterology.
2004;
126
469-475
50
Lee C W, Bociek G, Faught W.
A survey of practice in management of malignant ascites.
J Pain Symptom Manage.
1998;
16
96-101
51
Fulenwider J T, Galambos J D, Smith 3rd R B et al.
LeVeen vs Denver peritoneovenous shunts for intractable ascites of cirrhosis. A randomized, prospective trial.
Arch Surg.
1986;
121
351-355
52
Leveen H H, Christoudias G, Ip M et al.
Peritoneo-venous shunting for ascites.
Ann Surg.
1974;
180
580-591
53
Gines P, Arroyo V, Vargas V et al.
Paracentesis with intravenous infusion of albumin as compared with peritoneovenous shunting in cirrhosis with refractory ascites.
N Engl J Med.
1991;
325
829-835
54
Becker G, Galandi D, Blum H E.
Malignant ascites: systematic review and guideline for treatment.
Eur J Cancer.
2006;
42
589-597
55
Adam R A, Adam Y G.
Malignant ascites: past, present, and future.
J Am Coll Surg.
2004;
198
999-1011
56
Becker G.
Medical and palliative management of malignant ascites.
Cancer Treat Res.
2007;
134
459-467
57
Elias D, Gilly F, Boutitie F et al.
Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study.
J Clin Oncol.
2010;
28
63-68
58
Esquivel J, Sticca R, Sugarbaker P et al.
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Society of Surgical Oncology.
Ann Surg Oncol.
2007;
14
128-133
59
Seimetz D, Lindhofer H, Bokemeyer C.
Development and approval of the trifunctional antibody catumaxomab (anti-EpCAMxanti-CD3) as a targeted cancer immunotherapy.
Cancer Treat Rev.
2010;
36
458-467
60
Zeidler R, Mysliwietz J, Csanady M et al.
The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells.
Br J Cancer.
2000;
83
261-266
61
Zeidler R, Reisbach G, Wollenberg B et al.
Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing.
J Immunol.
1999;
163
1246-1252
62
Riesenberg R, Buchner A, Pohla H et al.
Lysis of prostate carcinoma cells by trifunctional bispecific antibodies (alpha EpCAM × alpha CD3).
J Histochem Cytochem.
2001;
49
911-917
63
Strohlein M A, Heiss M M.
Immunotherapy of peritoneal carcinomatosis.
Cancer Treat Res.
2007;
134
483-491
64
Heiss M M, Strohlein M A, Jager M et al.
Immunotherapy of malignant ascites with trifunctional antibodies.
Int J Cancer.
2005;
117
435-443
65
Kiewe P, Hasmuller S, Kahlert S et al.
Phase I trial of the trifunctional anti-HER2 x anti-CD3 antibody ertumaxomab in metastatic breast cancer.
Clin Cancer Res.
2006;
12
3085-3091
66
Heiss M M, Murawa P, Koralewski P et al.
The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II / III trial.
Int J Cancer.
2010;
127
2209-2221
67
Sugarbaker D J.
Multimodality management of malignant pleural mesothelioma: introduction.
Semin Thorac Cardiovasc Surg.
2009;
21
95-96
Dr. med. M. A. Ströhlein
Klinikum Köln-Merheim · Universität Witten / Herdecke · Klinik für Viszeral-, Gefäß- und Transplantationschirurgie
Ostmerheimer Str. 200
51109 Köln
Deutschland
Phone: +49 / 2 21 / 89 07 37 70
Fax: +49 / 2 21 / 89 07 85 61
Email: stroehleinm@kliniken-koeln.de